Drug Trial Radar · NCT03608033
Study of the Safety and Efficacy of OMS721 in Patients With Immunoglobulin A (IgA) Nephropathy
Last checked: Nov 20, 2026Latest source record: Dec 9, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
360
Actual
Start
Apr 5, 2018
Primary completion
Jan 12, 2024
Study completion Jan 12, 2024
Sponsor
- Lead sponsor
- Omeros CorporationIndustry
- Sponsor type
- Industry
- First posted
- Jul 31, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this study is to evaluate the effect of OMS721 on 24-hour urine protein excretion (UPE) in IgA nephropathy (IgAN) patients with high baseline proteinuria (high-risk proteinuria group; 24-hour UPE ≥ 2 g/day) assessed at 36 weeks from baseline.
Conditions
- IgA Nephropathy
Interventions
OMS721Biological
Biological: OMS721
Vehicle (D5W or saline)Other
5% Dextrose in water or normal saline solution
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent Change in 24-hour UPE in g/Day Compared to BaselineTime frame: 36 Weeks
Locations
139 sites in 23 countries. Site status is shown where the registry gives one.
Omeros Investigational Site
Florence, Alabama
Omeros Investigational Site
Mesa, Arizona
Omeros Investigation Sites
Phoenix, Arizona
Omeros Investigational Site
Scottsdale, Arizona
Omeros Investigational Site
Scottsdale, Arizona
Omeros Investigational Site
Los Angeles, California
Omeros Investigational Site
Los Angeles, California
Omeros Investigational Site
Northridge, California
Omeros Investigational Site
San Dimas, California
Omeros Investigational Site
San Francisco, California
Omeros Investigational Site
Stanford, California
Omeros Investigational Site
Torrance, California
Omeros Investigational Site
Denver, Colorado
Omeros Investigational Site
Miami, Florida
Omeros Investigational Site
Miami Lakes, Florida
Omeros Investigational Site
Lawrenceville, Georgia
Omeros Investigational Site
Chicago, Illinois
Omeros Investigational Site
Iowa City, Iowa
Omeros Investigational Site
Boston, Massachusetts
Omeros Investigational Site
Springfield, Massachusetts
Omeros Investigational Site
Minneapolis, Minnesota
Omeros Investigational Site
Rochester, Minnesota
Omeros Investigational Site
St Louis, Missouri
Omeros Investigational Site
Fresh Meadows, New York
Omeros Investigational Site
New York, New York
Omeros Investigational Site
Cincinnati, Ohio
Omeros Investigational Site
Columbus, Ohio
Omeros Investigational Site
Philadelphia, Pennsylvania
Omeros Investigational Site
Charleston, South Carolina
Omeros Investigational Site
Chattanooga, Tennessee
Omeros Investigational Site
Amarillo, Texas
Omeros Investigational Site
Dallas, Texas
Omeros Investigational Site
Houston, Texas
Omeros Investigational Site
Milwaukee, Wisconsin
Omeros Investigational Site
Buenos Aires, Argentina
Omeros Investigational Site
Córdoba, Argentina
Omeros Investigational Site
Salta, Argentina
Omeros Investigational Site
Posadas, Misiones Province, Argentina
Omeros Investigational Site
Garran, Australian Capital Territory, Woden, Australia
Omeros Investigational Site
Footscray, Saint Albans, Australia
Showing 40 of 139 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.